AAPL325.28+9.94 (+3.15%) ▲|ABBV253.57+2.66 (+1.06%) ▲|ABT103.46-1.77 (-1.68%) ▼|ACN177.87+2.07 (+1.18%) ▲|ADBE249.01-5.85 (-2.30%) ▼|AMAT456.75-12.10 (-2.58%) ▼|AMD505.31-15.79 (-3.03%) ▼|AMGN382.46-8.82 (-2.25%) ▼|AMT172.51-2.92 (-1.66%) ▼|AMZN251.64-0.76 (-0.30%) ▼|AVGO361.91-2.47 (-0.68%) ▼|AXP320.62-1.18 (-0.37%) ▼|BA204.88-1.55 (-0.75%) ▼|BAC62.50-0.18 (-0.28%) ▼|BKNG174.23+0.80 (+0.46%) ▲|BLK1,062.91-9.12 (-0.85%) ▼|BMY63.92-0.50 (-0.77%) ▼|BNY162.53+0.02 (+0.01%) ▲|BRK-B506.43-0.29 (-0.06%) ▼|C138.20+0.40 (+0.29%) ▲|CAT803.92-11.64 (-1.43%) ▼|CL87.93-0.10 (-0.11%) ▼|CMCSA25.19+0.60 (+2.44%) ▲|COF207.00-3.86 (-1.83%) ▼|COP137.45+0.92 (+0.67%) ▲|COST901.51-1.09 (-0.12%) ▼|CRM242.83-1.33 (-0.54%) ▼|CSCO107.85-1.58 (-1.44%) ▼|CVS95.44+0.06 (+0.06%) ▲|CVX213.10-0.72 (-0.33%) ▼|DE677.02-0.20 (-0.03%) ▼|DHR201.03-3.83 (-1.87%) ▼|DIS105.12+0.94 (+0.90%) ▲|DUK119.59-0.85 (-0.70%) ▼|EMR147.71-2.63 (-1.75%) ▼|FDX311.71+2.52 (+0.82%) ▲|GD354.24+1.57 (+0.45%) ▲|GE323.54-1.88 (-0.58%) ▼|GEV923.32-27.72 (-2.91%) ▼|GILD144.92-0.73 (-0.50%) ▼|GM85.87+2.11 (+2.52%) ▲|GOOG330.30+1.92 (+0.58%) ▲|GOOGL332.68+2.03 (+0.61%) ▲|GS1,017.64-11.14 (-1.08%) ▼|HD305.04-5.41 (-1.74%) ▼|HON201.98-2.95 (-1.44%) ▼|IBM233.73-6.21 (-2.59%) ▼|INTC101.00-5.24 (-4.93%) ▼|INTU311.98-1.96 (-0.63%) ▼|ISRG360.87+7.63 (+2.16%) ▲|JNJ266.59-0.49 (-0.18%) ▼|JPM353.02-1.69 (-0.48%) ▼|KO88.00+0.45 (+0.51%) ▲|LIN461.04-5.62 (-1.20%) ▼|LLY1,123.98-0.23 (-0.02%) ▼|LMT528.40+3.94 (+0.75%) ▲|LOW196.31-2.29 (-1.15%) ▼|LRCX299.98-15.86 (-5.02%) ▼|MA564.61-2.89 (-0.51%) ▼|MCD252.96-0.52 (-0.21%) ▼|MDLZ62.28-0.14 (-0.22%) ▼|MDT91.62-0.27 (-0.29%) ▼|META643.23-10.47 (-1.60%) ▼|MMM162.74-1.66 (-1.01%) ▼|MO68.57+0.68 (+1.00%) ▲|MRK144.69-2.85 (-1.93%) ▼|MS213.33-2.02 (-0.94%) ▼|MSFT490.76-0.90 (-0.18%) ▼|MU981.93-45.84 (-4.46%) ▼|NEE82.68+0.03 (+0.04%) ▲|NFLX75.86-0.17 (-0.22%) ▼|NKE36.59-0.76 (-2.03%) ▼|NOW131.14+0.03 (+0.02%) ▲|NVDA218.38-5.29 (-2.37%) ▼|ORCL153.94-7.69 (-4.76%) ▼|PEP136.87+0.18 (+0.13%) ▲|PFE27.53-0.26 (-0.92%) ▼|PG143.06+0.42 (+0.30%) ▲|PLTR165.70-3.83 (-2.26%) ▼|PM189.55+3.84 (+2.07%) ▲|QCOM177.81+1.41 (+0.80%) ▲|RTX197.47-0.08 (-0.04%) ▼|SBUX99.40-0.65 (-0.64%) ▼|SCHW107.06+0.52 (+0.48%) ▲|SO88.07-0.28 (-0.31%) ▼|SPG205.23+0.70 (+0.34%) ▲|T25.62+0.47 (+1.87%) ▲|TMO602.65-3.05 (-0.50%) ▼|TMUS176.76-0.58 (-0.33%) ▼|TSLA363.84-3.98 (-1.08%) ▼|TXN258.73-2.86 (-1.09%) ▼|UBER72.38+1.30 (+1.83%) ▲|UNH389.44-3.62 (-0.92%) ▼|UNP285.24+0.50 (+0.18%) ▲|UPS99.84+0.62 (+0.62%) ▲|USB62.24+0.13 (+0.20%) ▲|V367.19-0.20 (-0.05%) ▼|VZ49.91+0.17 (+0.33%) ▲|WFC89.12-0.56 (-0.62%) ▼|WMT105.81-0.02 (-0.02%) ▼|XOM165.50+1.27 (+0.77%) ▲|AAPL325.28+9.94 (+3.15%) ▲|ABBV253.57+2.66 (+1.06%) ▲|ABT103.46-1.77 (-1.68%) ▼|ACN177.87+2.07 (+1.18%) ▲|ADBE249.01-5.85 (-2.30%) ▼|AMAT456.75-12.10 (-2.58%) ▼|AMD505.31-15.79 (-3.03%) ▼|AMGN382.46-8.82 (-2.25%) ▼|AMT172.51-2.92 (-1.66%) ▼|AMZN251.64-0.76 (-0.30%) ▼|AVGO361.91-2.47 (-0.68%) ▼|AXP320.62-1.18 (-0.37%) ▼|BA204.88-1.55 (-0.75%) ▼|BAC62.50-0.18 (-0.28%) ▼|BKNG174.23+0.80 (+0.46%) ▲|BLK1,062.91-9.12 (-0.85%) ▼|BMY63.92-0.50 (-0.77%) ▼|BNY162.53+0.02 (+0.01%) ▲|BRK-B506.43-0.29 (-0.06%) ▼|C138.20+0.40 (+0.29%) ▲|CAT803.92-11.64 (-1.43%) ▼|CL87.93-0.10 (-0.11%) ▼|CMCSA25.19+0.60 (+2.44%) ▲|COF207.00-3.86 (-1.83%) ▼|COP137.45+0.92 (+0.67%) ▲|COST901.51-1.09 (-0.12%) ▼|CRM242.83-1.33 (-0.54%) ▼|CSCO107.85-1.58 (-1.44%) ▼|CVS95.44+0.06 (+0.06%) ▲|CVX213.10-0.72 (-0.33%) ▼|DE677.02-0.20 (-0.03%) ▼|DHR201.03-3.83 (-1.87%) ▼|DIS105.12+0.94 (+0.90%) ▲|DUK119.59-0.85 (-0.70%) ▼|EMR147.71-2.63 (-1.75%) ▼|FDX311.71+2.52 (+0.82%) ▲|GD354.24+1.57 (+0.45%) ▲|GE323.54-1.88 (-0.58%) ▼|GEV923.32-27.72 (-2.91%) ▼|GILD144.92-0.73 (-0.50%) ▼|GM85.87+2.11 (+2.52%) ▲|GOOG330.30+1.92 (+0.58%) ▲|GOOGL332.68+2.03 (+0.61%) ▲|GS1,017.64-11.14 (-1.08%) ▼|HD305.04-5.41 (-1.74%) ▼|HON201.98-2.95 (-1.44%) ▼|IBM233.73-6.21 (-2.59%) ▼|INTC101.00-5.24 (-4.93%) ▼|INTU311.98-1.96 (-0.63%) ▼|ISRG360.87+7.63 (+2.16%) ▲|JNJ266.59-0.49 (-0.18%) ▼|JPM353.02-1.69 (-0.48%) ▼|KO88.00+0.45 (+0.51%) ▲|LIN461.04-5.62 (-1.20%) ▼|LLY1,123.98-0.23 (-0.02%) ▼|LMT528.40+3.94 (+0.75%) ▲|LOW196.31-2.29 (-1.15%) ▼|LRCX299.98-15.86 (-5.02%) ▼|MA564.61-2.89 (-0.51%) ▼|MCD252.96-0.52 (-0.21%) ▼|MDLZ62.28-0.14 (-0.22%) ▼|MDT91.62-0.27 (-0.29%) ▼|META643.23-10.47 (-1.60%) ▼|MMM162.74-1.66 (-1.01%) ▼|MO68.57+0.68 (+1.00%) ▲|MRK144.69-2.85 (-1.93%) ▼|MS213.33-2.02 (-0.94%) ▼|MSFT490.76-0.90 (-0.18%) ▼|MU981.93-45.84 (-4.46%) ▼|NEE82.68+0.03 (+0.04%) ▲|NFLX75.86-0.17 (-0.22%) ▼|NKE36.59-0.76 (-2.03%) ▼|NOW131.14+0.03 (+0.02%) ▲|NVDA218.38-5.29 (-2.37%) ▼|ORCL153.94-7.69 (-4.76%) ▼|PEP136.87+0.18 (+0.13%) ▲|PFE27.53-0.26 (-0.92%) ▼|PG143.06+0.42 (+0.30%) ▲|PLTR165.70-3.83 (-2.26%) ▼|PM189.55+3.84 (+2.07%) ▲|QCOM177.81+1.41 (+0.80%) ▲|RTX197.47-0.08 (-0.04%) ▼|SBUX99.40-0.65 (-0.64%) ▼|SCHW107.06+0.52 (+0.48%) ▲|SO88.07-0.28 (-0.31%) ▼|SPG205.23+0.70 (+0.34%) ▲|T25.62+0.47 (+1.87%) ▲|TMO602.65-3.05 (-0.50%) ▼|TMUS176.76-0.58 (-0.33%) ▼|TSLA363.84-3.98 (-1.08%) ▼|TXN258.73-2.86 (-1.09%) ▼|UBER72.38+1.30 (+1.83%) ▲|UNH389.44-3.62 (-0.92%) ▼|UNP285.24+0.50 (+0.18%) ▲|UPS99.84+0.62 (+0.62%) ▲|USB62.24+0.13 (+0.20%) ▲|V367.19-0.20 (-0.05%) ▼|VZ49.91+0.17 (+0.33%) ▲|WFC89.12-0.56 (-0.62%) ▼|WMT105.81-0.02 (-0.02%) ▼|XOM165.50+1.27 (+0.77%) ▲|
30.6 C
New York
Thursday, September 10, 2026

Tag: months

Resonate Releases Q3 Consumer Trends Forecast

New Data Reveals Deepening Economic Anxiety Among U.S. Consumers, Driving Significant Spending Shifts RESTON, Va., June 13, 2025 /PRNewswire/ -- Latest data from the Consumer...

Heimar hf.: Acquisition of Gróska Completed

The acquisition by Heimar hf. ("Heimar" or the "Company") of all shares in Gróska ehf. (“Gróska”) and Gróðurhúsið ehf. (“Gróðurhúsið”) (the “Transaction”), which was initially announced on 23 April this year, has now been completed. 

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that dosing has commenced at the prestigious Weill Cornell Medicine Multiple Sclerosis Center in New York City, in its ongoing Phase 2 clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This fifth site complements existing sites at Yale University, Johns Hopkins University, Brigham and Women's Hospital, and the University of Massachusetts.

Thinkific Announces Closing of Secondary Offering of Approximately C$14.5 Million of Rhino Group’s Shares

/NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ VANCOUVER, BC, June 13, 2025 /CNW/ - Thinkific Labs Inc. ("Thinkific" or the...

Baltimore Expands Use of Evolve™ Rodent Birth Control Following Successful Pilot

Full Scale Implementation Expected SURPRISE, Ariz., June 13, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), a leader in fertility control solutions...

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

CLEVELAND, June 13, 2025 /PRNewswire/ -- Primary Investigator, Bernardo Cortese MD, proudly announces the successful completion of patient enrollment in the TRANSFORM II randomized...

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib
New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib

Bpce: BPCE signs a Memorandum of Understanding to acquire novobanco, Portugal’s fourth-largest bank

BPCE signs a Memorandum of Understanding to acquire novobanco, Portugal’s fourth-largest bank

Global News and The Local Win CJF Excellence Awards

TORONTO, June 12, 2025 /CNW/ - Global News is this year's recipient of the CJF Jackman Award for Excellence in Journalism in the large-media category, for...

Agoda Unveils ‘Europe to Asia Summer Travel Trends’ – Thailand Tops the Charts, Vietnam Joins the Top 5

HONG KONG, June 13, 2025 /PRNewswire/ -- As Europe gears up for its summer holidays, digital travel platform Agoda reveals that Thailand remains the...

Cloud Mining Demand Soars as VNBTC’s Cardano Contract Sells Out, Drawing Attention from Global Cardano Investors

Cardano (ADA) founder announced the launch of Cardinal, a DeFi protocol built to enable Bitcoin holders to access services like staking and lending. Following the announcement, the ADA price, which has dropped by over 10% in the past month, started looking bullish. Now the weekly charts show a 5% increase and about a 2% increase in the past 24 hours. Could the Cardinal news push ADA price higher?
Cardano (ADA) founder announced the launch of Cardinal, a DeFi protocol built to enable Bitcoin holders to access services like staking and lending. Following the announcement, the ADA price, which has dropped by over 10% in the past month, started looking bullish. Now the weekly charts show a 5% increase and about a 2% increase in the past 24 hours. Could the Cardinal news push ADA price higher?

WALL FINANCIAL CORPORATION ANNOUNCES Q1 2026 FISCAL RESULTS

VANCOUVER, BC, June 12, 2025 /CNW/ - Wall Financial Corporation (TSX: WFC) (the "Company") released its operating results and financial statements for the three...

State Farm Investigation Must Conclude Before Rate Hike Approved Says Consumer Watchdog

LOS ANGELES, June 12, 2025 /PRNewswire/ -- Consumer Watchdog issued the following statement on Insurance Commissioner Ricardo Lara's announcement today of a market conduct...

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMonths